The ALRT Diabetes Management System in Action

The ALRT Diabetes Management System in Action

New video presentation shows how health care providers use the features of ALRT’s Diabetes Management System to support patients with Type 2 Diabetes.

(October 23, 2017 -- RICHMOND, VA) Following the recent FDA clearance of the Company’s Insulin Dose Adjustment feature and release of its patent pending Predictive A1C innovation, ALR Technologies Inc. (“ALRT” or the “Company”) has released a new video presentation to show how health care providers are supported by the ALRT Diabetes Management System.

The latest video titled “Details of the ALRT Diabetes Management System” provides a tour of the ALRT diabetes management system from the perspective of a healthcare provider monitoring a group of diabetes patients under his or her care. The healthcare provider is able to view the progress and history of patient’s blood glucose date and the Predictive A1C trend for specific patients, and make decisions on adjustment of medicines within the system. ALRT provides in an integrated view, dosage information for all major diabetes medicines as well as the American Diabetes Association and American Association of Clinical Endocrinologists clinical guidelines for insulin dosage.

“Details of the ALRT Diabetes Management System” is the final video in a series of six videos released by ALRT last week, which highlight key features of the ALRT diabetes management system. To view the videos please go to the Company’s YouTube channel – www.youtube.com/ALRTechnologies.


Note to Readers: screenshots of the ALRT Diabetes Management System include names of medicines prescribed for the treatment of Type 2 Diabetes, including the following:

  • Metformin and Metformin extended release
    Carbophage SR, Fortamet, Glucophage XR, Glumetza, Riomet

  • GLP-1-RA
    Adlyxin, Bydureon, Byetta, Tanzeum, Trulicity, Victoza

  • GLP-1-RA Combinations
    Soliqua 100-33, Xultophy

  • AGI
    Glyset, Precose

  • SGL2-I
    Farxiga, Invokana, Jardiance

  • SGL2-I Combinations
    Invokamet, Synjardy, Xigduo, Glyxambi

  • Sulfa
    Amaryl, Diabeta, Glucotrol, Micronase

  • Sulfa Combinations
    Amaryl M, Glucovance, Metaglip, Avandaryl, Duetact

  • GLN
    Glufast, Prandin, Starlix

  • GLN Combinations
    PrandiMet

  • DPP-4-I
    Januvia, Nesina, Onglyza, Tradjenta

  • DPP-4-I Combinations
    Janumet, Jentadueto, Kazano, Kombiglyze XR, Glyxambi, Oseni

  • TZD
    Actos, Avandia

  • TZD Combinations
    Actoplus Met, Avandamet, Oseni, Avandaryl, Duetact

INSULINS

  • Intermediate
    Humulin N, Novolin N

  • Long acting
    Basaglar, Lantus, Levemir, Toujeo, Tresiba

  • Premixed
    Humalog Mix 50/50, Humalog Mix 75/25, Humulin 70/30, Novolin 70/30, Novolog Mix 70/30

  • Rapid acting
    Afrezza, Apidra, Flasp, Humalog, Novolog

  • Short acting
    Humulin R, Novolin R


About ALR Technologies Inc.

ALR Technologies is a medical device company providing an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters. The System processes and streamlines collected data to support clinicians and caregivers to improve patient outcomes and assist health plans to optimize their investments in chronic disease care. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.

Contact

Ken Robulak
Phone: 1.877.257.8242
Email: info@alrt.com